These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 7511944)

  • 1. Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences.
    van Giezen JJ; Minkema J; Bouma BN; Jansen JW
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):869-75. PubMed ID: 7511944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method].
    Ogloblina OG; Saburova OS; Semenova OA; Belova LA
    Biokhimiia; 1994 Jan; 59(1):62-8. PubMed ID: 7509643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activation and lysis of blood clots induced by cells in vitro.
    Knox P; Crooks S
    J Cell Physiol; 1988 Jun; 135(3):467-73. PubMed ID: 2456288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis.
    Reed GL; Matsueda GR; Haber E
    Trans Assoc Am Physicians; 1991; 104():21-8. PubMed ID: 1845147
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombomodulin-dependent effect of factor V Leiden mutation on the cross-linking of α2-plasmin inhibitor to fibrin and its consequences on fibrinolysis.
    Koncz Z; Bagoly Z; Haramura G; Mezei ZA; Muszbek L
    Thromb Res; 2012 Sep; 130(3):528-34. PubMed ID: 22704462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
    Jansen JW; Haverkate F; Koopman J; Nieuwenhuis HK; Kluft C; Boschman TA
    Thromb Haemost; 1987 Apr; 57(2):171-5. PubMed ID: 2440124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
    Mimuro J; Kimura S; Aoki N
    J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
    Sakata Y; Aoki N
    J Clin Invest; 1980 Feb; 65(2):290-7. PubMed ID: 6444305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
    Zabczyk M; Natorska J; Bagoly Z; Sarkady F; Barath B; Katona E; Bryk A; Zettl K; Wisniewski JR; Undas A
    J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
    Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
    Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
    J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA; Booth NA; Croll AM; Bennett B
    Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysis of clots prepared from whole blood and plasma.
    Taylor FB; Carroll RC; Gerrard J; Esmon CT; Radcliffe RD
    Fed Proc; 1981 May; 40(7):2092-8. PubMed ID: 7194803
    [No Abstract]   [Full Text] [Related]  

  • 14. FXIII polymorphisms, fibrin clot structure and thrombotic risk.
    Kobbervig C; Williams E
    Biophys Chem; 2004 Dec; 112(2-3):223-8. PubMed ID: 15572253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development.
    Landskroner K; Olson N; Jesmok G
    J Vasc Interv Radiol; 2005 Mar; 16(3):369-77. PubMed ID: 15758133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
    Reed GL; Matsueda GR; Haber E
    Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
    van Giezen JJ; Boon GI; Jansen JW; Bouma BN
    Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
    Korninger C; Collen D
    Thromb Haemost; 1981 Aug; 46(2):561-5. PubMed ID: 6795744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of activated factor XIII by polymorphonuclear granulocyte proteases within fibrin clot.
    Bagoly Z; Haramura G; Muszbek L
    Thromb Haemost; 2007 Aug; 98(2):359-67. PubMed ID: 17721618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.